Physician profile
Roberto Gugig
NPI 1639138852
$7,960.00
in general payments reported to CMS, 2019-2025
8 companies · $5,818 in 2025
The $5,818 reported for 2025 was more than what 91% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2023: $14.57 · 2024: $1,869 · 2025: $5,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,339 · Food and Beverage: $361 · Travel and Lodging: $1.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,339.05 |
| Food and Beverage | $361.08 |
| Travel and Lodging | $1.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $7,340.79 | 2024-2025 | Evis Exera II Small Intestinal Videoscope, Evis Exera III Duodenovideoscope |
| Boston Scientific Corporation | $235.58 | 2019-2025 | Exalt Model D |
| Medtronic, INC. | $172.54 | 2025 | Beacon |
| Alexion Pharmaceuticals, INC. | $122.67 | 2019 | |
| Pfizer INC. | $35.13 | 2019 | |
| Genzyme Corporation | $23.98 | 2024 | |
| Alcresta Therapeutics, INC. | $14.74 | 2019 | |
| Fresenius Kabi USA, LLC | $14.57 | 2023 | Smoflipid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Gugig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.